Menu Login / Registration Search
CZ

CLIA Centromere

Chemiluminescence kit for the detection of Centromere antibodies in human serum or plasma.

New
Catalog Number: CL-CEN050
Size: 50 tests
Regulatory status: CE IVD
Clinical topic: Immunology & Autoimmune Diseases
Diagnostic panel: Rheumatic Diseases
CLIA Centromere
  • Detection of anti-centromere antibodies (ACA), IgG class
  • Diagnosis of systemic sclerosis, highly specific for CREST syndrome
  • Evaluating patients with clinical signs and symptoms compatible with systemic sclerosis
  • Prediction of CREST syndrome
  • Prognostically significant in patients with Raynaud’s phenomenon
  • Intended for human serum and plasma
  • A mixture of recombinant CENP B and CENP A antigens used

The centromere is the part of a chromosome that links sister chromatids. Centromere proteins may become a target for anti-centromere antibodies (ACA). Most frequently, autoimmune reaction is directed against CENP A (17 kDa), CENP B (80 kDa), or CENP C (140 kDa). The CENP B is considered the most significant autoantigen from the group.

Antibodies to CENP B and CENP A are an important diagnostic marker for systemic sclerosis (scleroderma), found in 20-40% of patients. They are highly specific for the limited form of systemic sclerosis – CREST syndrome (calcinosis, Raynaud’s phenomenon, oesophageal motility abnormalities, sclerodactylia, and telangiectasia). Contrary, they are very rarely found in the diffusion form of the disease. The presence of ACA may predate the clinical diagnosis of CREST syndrome by up to several years. Their presence is prognostically significant in patients with Raynaud’s phenomenon. However, ACA have also been described in some patients with primary biliary cirrhosis and may occur in patients with rheumatoid arthritis or lupus erythematosus.

Antigen Used: Mixture of recombinant CENP B and CENP A antigens.

Technical specifications

Technical data
References
Related Products
Downloads

Technical data

Assay stability30 days on board stability / In use stability until the expiration date at storage temperature 2-8 °C
Sample matrix Serum, Plasma
Sample volume10 µL
Measuring range0,5-320 U/ml
Assay/kit contentReagent Cartridge with specific reagents for the assay, magnetic particles, calibrators
Complementary productsWash buffer, Anchor® Tips, Stackable cuvettes, Trigger solutions
Note

The kits are CE-IVD certified and intended for professional use.

References

References to CLIA Centromere

  • Powell FC, Winkelmann RK, Venencie-Lemarchand F, Spurbeck JL, Schroeter AL. The anticentromere antibody: disease specificity and clinical significance. Mayo Clin Proc. 1984 Oct;59(10):700-6. doi: 10.1016/s0025-6196(12)62059-x. PMID: 6384675.
    See more on PubMed
  • Nihtyanova SI, Denton CP. Autoantibodies as predictive tools in systemic sclerosis. Nat Rev Rheumatol. 2010 Feb;6(2):112-6. doi: 10.1038/nrrheum.2009.238. PMID: 20125179.
    See more on PubMed
  • van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, Matucci-Cerinic M, Naden RP, Medsger TA Jr, Carreira PE, Riemekasten G, Clements PJ, Denton CP, Distler O, Allanore Y, Furst DE, Gabrielli A, Mayes MD, van Laar JM, Seibold JR, Czirjak L, Steen VD, Inanc M, Kowal-Bielecka O, Müller-Ladner U, Valentini G, Veale DJ, Vonk MC, Walker UA, Chung L, Collier DH, Ellen Csuka M, Fessler BJ, Guiducci S, Herrick A, Hsu VM, Jimenez S, Kahaleh B, Merkel PA, Sierakowski S, Silver RM, Simms RW, Varga J, Pope JE. 2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative. Ann Rheum Dis. 2013 Nov;72(11):1747-55. doi: 10.1136/annrheumdis-2013-204424. PMID: 24092682.
    See more on PubMed
  • Ho KT, Reveille JD. The clinical relevance of autoantibodies in scleroderma. Arthritis Res Ther. 2003;5(2):80-93. doi: 10.1186/ar628. Epub 2003 Feb 12. PMID: 12718748; PMCID: PMC165038.
    See more on PubMed
  • Kajio N, Takeshita M, Suzuki K, Kaneda Y, Yamane H, Ikeura K, Sato H, Kato S, Shimizu H, Tsunoda K, Takeuchi T. Anti-centromere antibodies target centromere- kinetochore macrocomplex: a comprehensive autoantigen profiling. Ann Rheum Dis. 2020 Nov 18;80(5):651–9. doi: 10.1136/annrheumdis-2020-218881. Epub ahead of print. PMID: 33208344; PMCID: PMC8053351.
    See more on PubMed
  • Kallenberg CG. Anti-centromere antibodies (ACA). Clin Rheumatol. 1990 Mar;9(1 Suppl 1):136-9. doi: 10.1007/BF02205562. PMID: 2203592.
    See more on PubMed
  • Kuramoto N, Ohmura K, Ikari K, Yano K, Furu M, Yamakawa N, Hashimoto M, Ito H, Fujii T, Murakami K, Nakashima R, Imura Y, Yukawa N, Yoshifuji H, Taniguchi A, Momohara S, Yamanaka H, Matsuda F, Mimori T, Terao C. Anti-centromere antibody exhibits specific distribution levels among anti-nuclear antibodies and may characterize a distinct subset in rheumatoid arthritis. Sci Rep. 2017 Jul 31;7(1):6911. doi: 10.1038/s41598-017-07137-4. PMID: 28761166; PMCID: PMC5537247.
    See more on PubMed

Downloads

Safety information

Declaration of conformity

Find documents for the lot

Do you want to learn more about products? We're here for you.

Please fill in
all fields
marked *
Up